Teriparatide Induced Delayed Persistent Hypercalcemia

Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration. Persi...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiruchelvam, Nirosshan, Randhawa, Jaskirat, Sadiek, Happy, Kistangari, Gaurav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151495/
https://www.ncbi.nlm.nih.gov/pubmed/25202461
http://dx.doi.org/10.1155/2014/802473
_version_ 1782333024192430080
author Thiruchelvam, Nirosshan
Randhawa, Jaskirat
Sadiek, Happy
Kistangari, Gaurav
author_facet Thiruchelvam, Nirosshan
Randhawa, Jaskirat
Sadiek, Happy
Kistangari, Gaurav
author_sort Thiruchelvam, Nirosshan
collection PubMed
description Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration. Persistent hypercalcemia, although not observed in clinical trials, is rarely reported. The current case describes a rare complication of teriparatide induced delayed persistent hypercalcemia.
format Online
Article
Text
id pubmed-4151495
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41514952014-09-08 Teriparatide Induced Delayed Persistent Hypercalcemia Thiruchelvam, Nirosshan Randhawa, Jaskirat Sadiek, Happy Kistangari, Gaurav Case Rep Endocrinol Case Report Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration. Persistent hypercalcemia, although not observed in clinical trials, is rarely reported. The current case describes a rare complication of teriparatide induced delayed persistent hypercalcemia. Hindawi Publishing Corporation 2014 2014-08-18 /pmc/articles/PMC4151495/ /pubmed/25202461 http://dx.doi.org/10.1155/2014/802473 Text en Copyright © 2014 Nirosshan Thiruchelvam et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Thiruchelvam, Nirosshan
Randhawa, Jaskirat
Sadiek, Happy
Kistangari, Gaurav
Teriparatide Induced Delayed Persistent Hypercalcemia
title Teriparatide Induced Delayed Persistent Hypercalcemia
title_full Teriparatide Induced Delayed Persistent Hypercalcemia
title_fullStr Teriparatide Induced Delayed Persistent Hypercalcemia
title_full_unstemmed Teriparatide Induced Delayed Persistent Hypercalcemia
title_short Teriparatide Induced Delayed Persistent Hypercalcemia
title_sort teriparatide induced delayed persistent hypercalcemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151495/
https://www.ncbi.nlm.nih.gov/pubmed/25202461
http://dx.doi.org/10.1155/2014/802473
work_keys_str_mv AT thiruchelvamnirosshan teriparatideinduceddelayedpersistenthypercalcemia
AT randhawajaskirat teriparatideinduceddelayedpersistenthypercalcemia
AT sadiekhappy teriparatideinduceddelayedpersistenthypercalcemia
AT kistangarigaurav teriparatideinduceddelayedpersistenthypercalcemia

Ejemplares similares